Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Exelixis Inc (EXEL)

Exelixis Inc (EXEL)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 7,023,003
  • Shares Outstanding, K 313,387
  • Annual Sales, $ 987,540 K
  • Annual Income, $ 111,780 K
  • 60-Month Beta 1.07
  • Price/Sales 7.02
  • Price/Cash Flow 56.78
  • Price/Book 3.63
Trade EXEL with:

Options Overview

Details
  • Implied Volatility 42.22%
  • Historical Volatility 28.50%
  • IV Percentile 4%
  • IV Rank 14.20%
  • IV High 77.89% on 04/12/21
  • IV Low 36.32% on 09/02/20
  • Put/Call Vol Ratio 0.19
  • Today's Volume 1,516
  • Volume Avg (30-Day) 973
  • Put/Call OI Ratio 0.32
  • Today's Open Interest 35,004
  • Open Int (30-Day) 32,055

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/21
See More
  • Average Estimate 0.07
  • Number of Estimates 6
  • High Estimate 0.18
  • Low Estimate 0.03
  • Prior Year 0.21
  • Growth Rate Est. (year over year) -66.67%

Price Performance

See More
Period Period Low Period High Performance
1-Month
21.65 +3.51%
on 06/08/21
24.75 -9.45%
on 05/21/21
-1.93 (-7.93%)
since 05/18/21
3-Month
21.24 +5.51%
on 03/25/21
25.77 -13.04%
on 05/14/21
-0.45 (-1.97%)
since 03/18/21
52-Week
18.18 +23.27%
on 11/23/20
27.35 -18.06%
on 09/16/20
-0.06 (-0.27%)
since 06/18/20

Most Recent Stories

More News
Exelixis Chief Medical Officer Gisela M. Schwab, M.D., to Take Medical Leave of Absence

Exelixis, Inc. (Nasdaq: EXEL) announced that, effective today, Gisela M. Schwab, M.D., the company's President, Product Development and Medical Affairs and Chief Medical Officer, has begun a medical leave...

EXEL : 22.41 (+1.27%)
Exelixis (EXEL) & Bristol Myers Team Up for Genitourinary Cancers

Exelixis (EXEL) collaborates with Bristol Myers to evaluate its next-generation tyrosine kinase inhibitor in combination with immuno-oncology therapies in advanced solid tumors.

BMY : 66.47 (-0.45%)
EXEL : 22.41 (+1.27%)
NKTR : 17.00 (-1.39%)
RGEN : 197.34 (-1.15%)
Exelixis Announces Clinical Trial Collaboration and Supply Agreement with Bristol Myers Squibb to Evaluate XL092 in Combination with Immuno-oncology Therapies in Advanced Solid Tumors

Exelixis, Inc. (Nasdaq: EXEL) today announced a clinical trial collaboration and supply agreement with Bristol-Myers Squibb Company (NYSE: BMY) for STELLAR-002, a new phase 1b trial evaluating XL092 in...

BMY : 66.47 (-0.45%)
NKTR : 17.00 (-1.39%)
EXEL : 22.41 (+1.27%)
Exelixis and Ipsen Announce Detailed Results from Phase 3 COSMIC-311 Pivotal Trial of Cabozantinib in Patients with Previously Treated Radioactive Iodine-Refractory Differentiated Thyroid Cancer Presented at ASCO 2021

--- Results from COSMIC-311 served as basis for Exelixis' recent supplemental New Drug Application to U.S. Food and Drug Administration -

EXEL : 22.41 (+1.27%)
IPN : 34.71 (-0.54%)
IPSEY : 26.7900 (-0.96%)
Exelixis Announces Consistent Efficacy Benefits Across Subgroups of Phase 3 CheckMate -9ER Trial of CABOMETYX(R) (cabozantinib) in Combination with OPDIVO(R) (nivolumab) as a First-line Treatment for Patients with Advanced Renal Cell Carcinoma

--- Data to be presented during the 2021 American Society of Clinical Oncology's Annual Meeting -

EXEL : 22.41 (+1.27%)
Exelixis Announces Quality-Adjusted Survival Benefit Demonstrated in Analysis of Phase 3 CheckMate -9ER Trial of CABOMETYX(R) (cabozantinib) in Combination with OPDIVO(R) (nivolumab) in Patients with Previously Untreated Advanced Renal Cell Carcinoma

--- Data to be presented during the 2021 American Society of Clinical Oncology's Annual Meeting -

EXEL : 22.41 (+1.27%)
Exelixis Announces Positive Phase 2 Results for CABOMETYX(R) (cabozantinib) in Combination with OPDIVO(R) (nivolumab) in Patients with Metastatic Non-Clear Cell Renal Cell Carcinoma at ASCO 2021

--- Data to be presented during the 2021 American Society of Clinical Oncology's Annual Meeting -

EXEL : 22.41 (+1.27%)
Exelixis to Webcast Fireside Chats as Part of Virtual Investor Conferences in June

Exelixis, Inc. (Nasdaq: EXEL) today announced that members of the company's management team will participate in fireside chats at the following virtual investor conferences in June:

EXEL : 22.41 (+1.27%)
Exelixis (EXEL) Reports Encouraging Data From Prostate Cancer Study

Exelixis (EXEL) announces encouraging results from the cohort 6 of a phase Ib study of Cabometyx in combination with Tecentriq.

RHHBY : 47.0800 (-0.86%)
EXEL : 22.41 (+1.27%)
BMY : 66.47 (-0.45%)
RGEN : 197.34 (-1.15%)
Liver Cancer Therapeutics Market Size & Business Planning, Innovation to See Modest Growth

Japan, Japan, Tue, 25 May 2021 01:49:28 / Comserve Inc. / -- Liver Cancer Therapeutics Market With Top Countries Data, Industry Analysis , Size, Share, Revenue, Prominent Players, Developing Technologies,...

ABBV : 113.12 (-1.55%)
AMGN : 238.68 (-0.86%)
BAYRY : 15.7300 (-1.47%)
BMY : 66.47 (-0.45%)
CLSN : 1.2400 (-6.06%)
ESALF : 101.0000 (+6.32%)
LLY : 218.55 (-1.65%)
EXEL : 22.41 (+1.27%)
MRK : 76.61 (-0.80%)
NVS : 93.01 (-1.21%)
PFE : 38.81 (-1.70%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Sell with a Weakening short term outlook on maintaining the current direction.

See More Share

Business Summary

Exelixis, Inc. is a biopharmaceutical company committed to developing small molecule therapies for the treatment of cancer. Exelixis is focusing its development and commercialization efforts primarily on COMETRIQ' (cabozantinib), its wholly-owned inhibitor of multiple receptor tyrosine kinases. Another...

See More

Key Turning Points

3rd Resistance Point 23.43
2nd Resistance Point 22.96
1st Resistance Point 22.68
Last Price 22.41
1st Support Level 21.93
2nd Support Level 21.46
3rd Support Level 21.18

See More

52-Week High 27.35
Fibonacci 61.8% 23.85
Fibonacci 50% 22.76
Last Price 22.41
Fibonacci 38.2% 21.68
52-Week Low 18.18

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar